MedTrace Logo

A Study of OBP-301 With Radiation Therapy in Patients With Esophageal Cancer

NCT03213054 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2018-09-26

No results posted yet for this study

Summary

This is a phase 1 study to evaluate safety and tolerability of Telomelysin (OBP-301) in combination with radiation therapy in patient with esophageal cancer who are not applicable to standard therapy.

Conditions

  • Esophageal Cancer

Interventions

BIOLOGICAL

OBP-301

OBP-301 administration on the Day 1, Day 18 and Day 32

RADIATION

Radiation

Standard radiation therapy for esophageal cancer patient. total 60 Gy for 6 weeks

Sponsors & Collaborators

  • Oncolys BioPharma Inc

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-07
Primary Completion
2019-03-31
Completion
2019-06-30
FDA Drug
Yes

Countries

  • Japan

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03213054 on ClinicalTrials.gov